Saturday 17 October 2026 Export AMPH’s income statement to Excel — free account

Amphastar Pharmaceuticals, Inc.

AMPH Healthcare Drug Manufacturers Specialty & Generic

Amphastar Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.9 million, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 5.44%, EPS grew 4.55%, free cash flow grew 87.6% and total debt was flat, each against the same quarter a year earlier.

25.87 0.55 −2.08%

Follow AMPH

Alert me

Market cap: $1.1B
P/E: 14.9×
Fwd P/E: 14.7×
Dividend yield: —
F-score: 6/9
Altman Z: 2.54
Beneish M: −2.57
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.70

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	3	2	—	—	—	—	—	—	—	2	3	—

Insider Ownership 29.18%

Capital & Financial Ratios $m

Market Cap 1,120.00

Revenue 730.02

Net Income 78.55

Free Cash Flow 152.89

Net Debt 319.49

Current Ratio 2.40

Debt/Equity 0.80

P/E ratio 14.87

Fwd P/E 14.70

P/S ratio 1.55

P/B ratio 1.47

Past 5Y EPS Growth 132.31%

This Y EPS Growth (8.59%)

Next Y EPS Growth 7.09%

Next Y revenue growth 3.86%

Next 5Y EPS Growth 1.34%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 26.81%

10-year low 10-year high

P/S against its own 10 years 7.30%

10-year low 10-year high

P/B against its own 10 years 7.45%

10-year low 10-year high

EV/Sales against its own 10 years 8.37%

10-year low 10-year high

EV/FCF against its own 10 years 4.97%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	259	224	285	293
Receivables	115	138	161	147
Inventory	106	154	177	180
Other	—	—	—	—
	490	534	636	631

	2023	2024	2025	Q'26
Payables	93	157	148	251
ST’ Debt	0	0	2	2
Other	—	—	—	—
	225	174	158	263

Compound Annual Growth %

	10y	5y	3y
Sales	11.09%	15.53%	12.99%
Cash Flow	30.76%	22.21%	20.52%
Earnings	0.00%	133.84%	2.39%
Book Value	10.32%	11.94%	14.27%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	171	184	—	—	—
’25	171	174	192	183	720
’24	172	182	191	187	732
’23	140	146	181	178	644
’22	120	123	120	135	499
’21	103	102	112	121	438
’20	85	86	83	96	350

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	48	51	—	—	—
’25	35	36	53	33	156
’24	55	69	60	29	213
’23	40	55	64	24	184
’22	51	3	20	15	89
’21	23	32	3	40	98
’20	1	30	9	17	57

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	38	43	—	—	—
’25	24	23	47	25	119
’24	46	63	46	17	172
’23	31	46	54	14	145
’22	45	(3)	15	9	66
’21	15	26	(5)	34	71
’20	(7)	19	4	8	23

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.14	0.67	—	—	—
’25	0.51	0.64	0.37	0.51	2.03
’24	0.81	0.73	0.78	0.74	3.06
’23	0.50	0.49	0.91	0.68	2.60
’22	0.47	0.33	0.30	0.66	1.74
’21	0.10	0.16	0.59	0.39	1.25
’20	0.08	0.00	0.08	(0.13)	0.03

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	10.50	12.05	14.40	16.71	12.33	16.91	22.07	27.58	36.48	20.39	Analyst estimates 2026–2028 Powerpack
	High	21.75	19.95	22.74	25.43	22.69	23.85	44.46	67.66	65.92	39.01
People
People	Employees	1,541	1,644	2,078	2,027	1,980	1,761	1,615	1,761	2,028	1,976
	Revenue/emp, $m	0.17	0.15	0.14	0.16	0.18	0.25	0.31	0.37	0.36	0.36
Income, $m
Income, $m	Revenue	255	240	295	322	350	438	499	644	732	720
	Gross margin, %	40.83	37.68	36.31	40.92	40.97	45.63	49.87	54.49	51.08	49.46
	EBT	15	1	(10)	60	5	84	116	171	190	124
	EBT margin, %	5.73	0.52	(3.37)	18.68	1.33	19.22	23.26	26.59	25.93	17.17
	Net income	10	4	(7)	47	1	63	91	138	160	98
	Depreciation	15	16	17	18	22	23	25	49	59	60
Per share, $
Per share, $	Revenue	5.62	5.21	6.35	6.86	7.44	9.16	10.28	13.35	15.11	15.40
	Earnings	0.23	0.08	(0.12)	1.04	0.03	1.30	1.88	2.85	3.29	2.10
	Cash flow	0.85	0.85	0.82	0.89	1.22	2.05	1.84	3.80	4.41	3.34
	Capex	(0.47)	(0.72)	(0.91)	(0.88)	(0.72)	(0.57)	(0.49)	(0.79)	(0.85)	(0.79)
	Free cash flow	0.38	0.13	(0.09)	0.00	0.50	1.48	1.35	3.01	3.56	2.55
	Book value	7.26	7.24	7.85	9.10	9.54	9.33	10.89	13.25	15.12	16.88
	Shares, m	45	46	46	47	47	48	49	48	48	47
Valuation, ×
Valuation, ×	P/E	77.08	249.61	0.00	18.55	502.75	17.92	15.08	21.93	11.29	12.75
	P/S	3.29	3.68	3.13	2.81	2.70	2.54	2.74	4.67	2.46	1.74
	P/B	2.55	2.65	2.53	2.12	2.11	2.50	2.59	4.70	2.46	1.59
	EV/Sales	3.15	3.58	2.99	2.68	2.52	2.40	2.54	5.18	2.97	2.19
	EV/FCF	46.74	140.53	(221.59)	15,426.84	37.95	14.93	19.37	22.99	12.64	13.27
Cash, $m
Cash, $m	Operating cash flow	39	39	38	42	57	98	89	184	213	156
	Capex	(21)	(33)	(42)	(42)	(34)	(27)	(24)	(38)	(41)	(37)
	Free cash flow	17	6	(4)	0	23	71	66	145	172	119
Balance, $m
Balance, $m	Working capital	123	121	114	165	167	214	283	264	360	478
	Total debt	38	47	50	47	46	77	76	590	602	610
	Net debt	(37)	(25)	(43)	(42)	(63)	(62)	(102)	331	378	325
	Shareholders’ equity	329	334	364	428	449	446	529	639	732	789
Returns, %
Returns, %	ROA	2.40	0.83	(1.19)	8.89	0.23	9.54	12.93	12.20	10.32	6.12
	ROIC	3.28	(0.26)	(1.68)	(0.01)	1.78	11.39	15.76	12.69	11.57	7.88
	ROE	3.14	1.10	(1.64)	12.36	0.32	13.89	18.76	23.55	23.26	12.90

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
XERS Xeris Biopharma Holdings, Inc.	$1.8B	— (loss-making)	54.5×	+28.74% (above 0%: growing)	n/m	+8,403.09% (above 0%: growing)	86.41%	5.62%	Compare
ANIP ANI Pharmaceuticals, Inc.	$1.7B	14.9×	14.5×	+25.87% (above 0%: growing)	+194.59% (above 0%: growing)	−22.19% (below 0%: shrinking)	62.35%	15.21%	Compare
PAHC Phibro Animal Health Corporation	$1.5B	15.8×	11.1×	+4.77% (above 0%: growing)	+28.57% (above 0%: growing)	−35.73% (below 0%: shrinking)	33.88%	12.14%	Compare
ETON Eton Pharmaceuticals, Inc.	$1.5B	107×	40.3×	+98.59% (above 0%: growing)	n/m	−8.78% (below 0%: shrinking)	67.61%	34.04%	Compare
PCRX Pacira BioSciences, Inc.	$1.5B	104×	33.7×	+6.24% (above 0%: growing)	n/m	+502.51% (above 0%: growing)	77.05%	2.22%	Compare
CRON Cronos Group Inc.	$1.2B	16.1×	32.2×	+58.44% (above 0%: growing)	n/m	+2,279.22% (above 0%: growing)	53.67%	13.97%	Compare
AMPH Amphastar Pharmaceuticals, Inc.	$1.1B	14.9×	14.7×	+5.44% (above 0%: growing)	+4.55% (above 0%: growing)	+87.61% (above 0%: growing)	50.83%	21.60%
HROW Harrow, Inc.	$1.1B	— (loss-making)	134×	+10.85% (above 0%: growing)	n/m	−838.78% (below 0%: shrinking)	71.27%	(15.58%)	Compare
COLL Collegium Pharmaceutical, Inc.	$754.6M	15.2×	12.5×	+6.32% (above 0%: growing)	n/m	−2.14% (below 0%: shrinking)	55.18%	1.85%	Compare
Median of peers	$1.5B	15.9×	33.0×	+18.36%	—	−5.46%	64.98%	8.88%

All 86 Drug Manufacturers Specialty & Generic stocks →

Amphastar Pharmaceuticals, Inc. (AMPH) key facts

Concern: Amphastar Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.9 million, down 1.65% from fiscal 2024.
Amphastar Pharmaceuticals, Inc. (AMPH) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, AMPH traded at $25.87, a market capitalization of $1.1 billion.
Return on equity was 12.9% and debt-to-equity 0.80.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 2.54 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.